A Phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma

Cancer

Volumn 79, Issue 10, 1997, Pages 2016-2023

  Dunphy, Frank R ^a   Boyd, James H ^b   Kim, Han J ^b   Dunphy, Cherie H ^c   Harrison, Bruce R ^a   Dunleavy, Teresa L ^a   Rodriguez, Jack J ^a   McDonough, Erin M ^b   Minster, Jeffrey R ^c   Hilton, Jack G ^d  

^a S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

carboplatin; head and neck carcinoma; maximum tolerated dose; medical oncology; paclitaxel; Phase I; toxicity

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FEVER; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; NERVOUS SYSTEM DISEASES; NEUTROPENIA; PACLITAXEL; PREOPERATIVE CARE; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 0030976109     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970515)79:10<2016::AID-CNCR24>3.0.CO;2-W     Document Type: Article

References (17)

1. Fazekas JT, Sommer C, Kramer S. Adjuvant intravenous methotrexate or definitive radiotherapy alone for advanced squamous cancers of the oral cavity, oropharynx, supraglottic larynx, or hypopharynx: concluding report of an RTOG randomized trial on 638 patients. Int J Radiat Oncol Biol Phys 1980;6(5):533-41.
2. Cachin Y, Eschwege F. Combination of radiotherapy and surgery in the treatment of head and neck cancers. Cancer Treat Rev 1975;2:177-91.
3. Probert JC, Thompson RW, Bagshaw MA. Patterns of spread of distant metastases in head and neck cancer. Cancer 1974;33:127-33.
4. Amrein PC, Weitzman SA. Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-Fluorouracil. J Clin Oncol 1985;3:1632-9.
5. Al-Sarraf M. New approaches to the management of head and neck cancer: the role of chemotherapy. Advances in Oncology 1990;3:11-4.
6. Kish JA, Ensley JF, Jacobs J, Weaver A, Cummings G, Al-Sarraf M. A randomized trial of cisplatin (CACP) + 5-Fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 1985;56:2740-4.
7. Schaefer SD, Middleton R, Reisch J, Frenkel EP. Cis-platinum induction chemotherapy in the multi-modality initial treatment of advanced stage IV carcinoma of the head and neck. Cancer 1983;51:2168-74.
8. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxell FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
9. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
10. Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995;13(5):1152-9.
11. Speilmann M. Taxol® (paclitaxel) in patients with metastatic breast carcinoma who have failed prior chemotherapy: interim results of a multinational study. Oncology 1994;51:25-8.
12. Seidman AD, Tiersten A, Hudis C, Golub M, Barrett S, Yao TJ, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13(10):2575-81.
13. Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994; 12(2):241-8.
14. Younes A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-hodgkin's lymphoma. J Clin Oncol 1995;13(3):583-7.
15. Gianni L, Munzone E, Capri G, Villani F, Spreafico C, Tarenzi E, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995;87(15):1169-75.
16. Langer C, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13(8):1860-70.
17. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donhower RC. Clinical toxicities encountered with paclitaxel (Taxol®). Semin Oncol 1993;20(4 Suppl)3:1-15.